Anticoagulation therapy / / edited by Ozcan Basaran, Murat Biteker.
The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Rijeka, Croatia : : IntechOpen,, [2016] ©2016 |
| Year of Publication: | 2016 |
| Language: | English |
| Physical Description: | 1 online resource (140 pages) :; illustrations |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02218nam a2200433 i 4500 | ||
|---|---|---|---|
| 001 | 993545886104498 | ||
| 005 | 20240124175748.0 | ||
| 006 | m o d | ||
| 007 | cr#||||||||||| | ||
| 008 | 221017s2016 ci a o 000 0 eng d | ||
| 020 | |a 953-51-7309-X | ||
| 020 | |a 953-51-2667-9 | ||
| 035 | |a (CKB)4970000000099157 | ||
| 035 | |a (NjHacI)994970000000099157 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/66919 | ||
| 035 | |a (EXLCZ)994970000000099157 | ||
| 040 | |a NjHacI |b eng |e rda |c NjHacl | ||
| 041 | 0 | |a eng | |
| 050 | 4 | |a RM340 |b .A585 2016 | |
| 082 | 0 | 4 | |a 615.718 |2 23 |
| 100 | 1 | |a Basaran, Ozcan |4 edt | |
| 245 | 0 | 0 | |a Anticoagulation therapy / |c edited by Ozcan Basaran, Murat Biteker. |
| 260 | |b IntechOpen |c 2016 | ||
| 264 | 1 | |a Rijeka, Croatia : |b IntechOpen, |c [2016] | |
| 264 | 4 | |c ©2016 | |
| 300 | |a 1 online resource (140 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | |a Open access |f Unrestricted online access |2 star | ||
| 588 | |a Description based on: online resource; title from PDF information screen (InTech, viewed October 17, 2022). | ||
| 520 | |a The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists. | ||
| 546 | |a English | ||
| 650 | 0 | |a Anticoagulants (Medicine) | |
| 650 | 0 | |a Warfarin. | |
| 653 | |a Pharmacology | ||
| 776 | |z 953-51-2666-0 | ||
| 700 | 1 | |a Basaran, Ozcan, |e editor. | |
| 700 | 1 | |a Biteker, Murat, |e editor. | |
| 906 | |a BOOK | ||
| ADM | |b 2024-01-25 02:21:07 Europe/Vienna |f system |c marc21 |a 2019-04-13 22:04:18 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338038320004498&Force_direct=true |Z 5338038320004498 |b Available |8 5338038320004498 | ||